Business Context and Reporting Period
Company: Alcon, Inc. (Swiss corporation, majority-owned subsidiary of Nestlé S.A.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three and six months ended June 30, 2008
Filing Date: July 24, 2008
Alcon operates globally in the ophthalmic market through two segments: Alcon United States and Alcon International. The company markets pharmaceuticals, surgical equipment/devices, and consumer eye care products. Notably, subsequent to the reporting period, Nestlé sold approximately 74 million shares to Novartis AG, reducing Nestlé's stake to approximately 52% and granting Novartis a minority stake of slightly less than 25%.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended June 30, 2008 |
3 Months Ended June 30, 2007 |
6 Months Ended June 30, 2008 |
6 Months Ended June 30, 2007 |
|---|---|---|---|---|
| Sales | $1,735.2 | $1,471.5 | $3,271.6 | $2,794.2 |
| Gross Profit | $1,320.7 | $1,118.2 | $2,458.8 | $2,091.9 |
| Gross Margin % | 76.1% | 76.0% | 75.2% | 74.9% |
| Operating Income | $645.6 | $536.5 | $1,145.7 | $939.6 |
| Net Earnings | $566.4 | $448.4 | $995.8 | $794.6 |
| Diluted EPS | $1.88 | $1.48 | $3.30 | $2.62 |
| Operating Cash Flow | N/A | N/A | $1,072.0 | $346.7 |
| Cash & Equivalents (End of Period) | $2,236.8 | N/A | $2,236.8 | N/A |
| Total Debt (Short + Long Term) | $1,654.3 | N/A | $1,654.3 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Global sales increased 17.9% (Q3) and 17.1% (YTD) compared to the prior year. Approximately 6.7% to 6.8% of this growth was attributable to favorable foreign exchange rates; constant currency growth was 11.2% (Q3) and 10.3% (YTD).
- Profitability: Net earnings rose 26.3% (Q3) and 25.3% (YTD). The effective tax rate decreased significantly to 12.8% (Q3) and 13.6% (YTD) from 18.8% and 18.6% in the prior year, driven by geographic earnings mix and Swiss tax benefits.
- Segment Performance: International sales grew 28.9% (Q3) and 27.3% (YTD), outpacing U.S. growth of 7.0% and 6.5% respectively. Refractive sales surged 215.5% (Q3) and 185.3% (YTD) due to the inclusion of WaveLight AG, acquired in November 2007.
- One-Time Items: The 2007 prior period included $32.7 million in impairment losses related to refractive assets, which inflated the year-over-year comparison for operating income.
- Cash Flow: Operating cash flow improved dramatically to $1,072.0 million (YTD 2008) from $346.7 million (YTD 2007). The 2007 figure was depressed by $520.8 million in cash used to purchase trading securities, which were reclassified to investing activities in 2008 under new accounting standards.
Outlook, Risks, and Contingencies
- Shareholder Structure: Nestlé and Novartis have agreed to put/call options regarding Nestlé's remaining 52% stake, exercisable between January 1, 2010, and July 31, 2011. Novartis has a call option at $181/share; Nestlé has a put option at the lower of $181/share or a 20.5% premium to market price.
- Share Repurchases: The company halted all open market share repurchases in April 2008 following the Nestlé-Novartis agreement. A pro-rata repurchase program was terminated in March 2008.
- Legal Contingencies:
- Patent Litigation: Active lawsuits against generic manufacturers (Teva, Apotex, Barr) regarding Vigamox® and Patanol®. A settlement with Teva regarding Bayer patents delays generic entry until 2014, but litigation on Alcon's patent continues with judgment expected in H1 2009.
- Antitrust: Synergetics USA filed a lawsuit alleging anti-competitive behavior in the vitreoretinal surgical equipment market, seeking over $100 million. Alcon believes the claims are without merit and has filed a counterclaim.
- Product Development: The company terminated the development program for anecortave acetate for age-related macular degeneration following interim analysis showing no effect on primary endpoints. Collaboration with Amgen was also terminated.
- Market Risks: Significant exposure to foreign currency fluctuations and interest rate changes on floating-rate debt. A 10% decline in foreign exchange rates could decrease earnings before taxes by approximately $33.6 million.
Investor Verification Checklist
- Ownership Transition: Verify the status of the Nestlé-Novartis transaction and the implications of the put/call options on future corporate control.
- Patent Expirations: Monitor the outcome of the Teva litigation regarding the Alcon patent for Vigamox® (judgment expected H1 2009) and the Apotex/Barr litigation for Patanol®.
- Constant Currency Growth: Assess organic growth rates by stripping out the ~6.7% foreign exchange benefit to evaluate core operational performance.
- WaveLight Integration: Review the long-term profitability contribution of the WaveLight AG acquisition, noting that integration costs currently impact margins.
- Dividend Policy: Confirm future dividend sustainability given the halt in share repurchases and the significant cash outflow for dividends ($749.7 million in H1 2008).